List view / Grid view
Filter the results
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers have created an accurate mouse model of Duchenne muscular dystrophy (DMD), showing that TGFβ is a potential target for the condition.
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
Researchers demonstrated that ABCC4 is essential to signalling in the SHH subgroup of medulloblastomas and when expression was reduced in mice, the tumours shrank.
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
Cryogenic electron microscopy revealed that the vitamin B12 transporter on Mycobacterium tuberculosis acts like a non-selective sluice, transporting both the vitamin and antibiotics.
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
A new study has shown that the role of T cell-suppressing dendritic cells can be reversed in mice, indicating that immunotherapies could be improved with this method.
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
Researchers have used high-throughput screening to discover the best combinations of purified cannabinoids against gastrointestinal cancer cells.
The TAp63 tumour suppressor protein, two micro RNAs (miRNAs) and the AURKA gene can all suppress cutaneous squamous cell carcinoma (cuSCC) development, find researchers.
Researchers have optimised PROTAC substances to degrade and dispose of proteins that support cancers, by customising their structure and selecting the best ligases.
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
Researchers observed that deleting the IRE1-alpha gene caused beta cells to de-differentiate and then re-differentiate in mice, preventing immune system auto-activation.